Holger Monenschein received his PhD from the Technical University of Clausthal-Zellerfeld, Germany. Afterward, he moved to San Diego to conduct post doctoral studies in the group of Prof. K.C. Nicolaou at TSRI. Holger started his industry career in 2003 at Amgen, Inc. In 2010, Holger moved to Jupiter, Florida where he initiated medicinal chemistry research and discovery at the small biotech startup Envoy Therapeutics. . In 2013, Holger moved to Takeda California as part of Takeda's acquisition of Envoy. At Takeda he is now director of medicinal chemistry operations in the field of CNS and early target validation.